Long Term Treatment of Mild Cognitive Impairment (MCI) with Transdermal Nicotine: The MIND Study (Newhouse)
Multi-center clinical trial to test whether daily transdermal nicotine will produce sustained cognitive, clinical, and modify imaging and biochemical markers in patients with Mild Cognitive Impairment (MCI).
Phase 1 First-In-Human Study of the Muscarinic M1 Positive Allosteric Modulator VU319 (Newhouse)
Initial human safety and target engagement testing of a novel cholinergic drug developed at Vanderbilt for Alzheimer’s disease.
Connectivity Affecting the Antidepressant Response: The CAARE study (Taylor)
To understand the relationship between brain connectivity and how older adults respond to antidepressant medications and depression relapse.
Depressed Mood Improvement through Nicotine Dosing: D-MIND Study (Taylor)
The effects of transdermal nicotine on depression and memory performance in older adults with depression.
History of Major Depressive Disorder and Estradiol Effects on Psychosocial Stress Response and Emotional Episodic Memory (Albert).
Nicotinic Treatment of Post-Cancer Chemotherapy Subjective Cognitive Impairment (Vega, Newhouse).
Cholinergic Correlates of Age and Impaired Cognitive Ability in HIV-Positive Individuals (Kamkwalala, Newhouse).
Efficacy And Safety Study Of Crenezumab In Patients With Prodromal To Mild Alzheimer’s Disease (Newhouse).